The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

about

How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive.CD83 in Hodgkin lymphoma.

P2860

Q52668325-2B98E66D-BF80-4092-8434-F3616577AEA7 Q55040297-44825E6E-4A01-492F-9E1A-36FBF105E17E

P2860

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

Item

http://www.wikidata.org/entity/Q38700459

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh

2017年學術文章

@zh-hant

name

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

@en

type

Item

label

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

@en

prefLabel

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

@en

P1476

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

@en

P2093

Andreas Engert

http://www.w3.org/2001/XMLSchema#string

Dennis A Eichenauer

http://www.w3.org/2001/XMLSchema#string

P2860

Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.

A phase 2 multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma.

Risk of heart failure in survivors of Hodgkin lymphoma: effects of cardiac exposure to radiation and anthracyclines

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.

cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity.

A Phase II trial of the oral mTOR inhibitor everolimus in relapsed Hodgkin lymphoma

Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

P304

775-782

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17474086.2017.1350167

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28665214

http://www.w3.org/2001/XMLSchema#string

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

about

P2860

P2860

The evolving role of targeted drugs in the treatment of Hodgkin lymphoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698